{"id":"NCT03684044","sponsor":"Hoffmann-La Roche","briefTitle":"Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza","officialTitle":"A Phase III, Randomized, Double-Blind Placebo-Controlled, Multicenter Study To Evaluate the Efficacy and Safety of Baloxavir Marboxil in Combination With Standard-of-Care Neuraminidase Inhibitor in Hospitalized Participants With Severe Influenza","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-01-08","primaryCompletion":"2020-03-16","completion":"2020-03-16","firstPosted":"2018-09-25","resultsPosted":"2020-11-30","lastUpdate":"2021-01-06"},"enrollment":363,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Influenza"],"interventions":[{"type":"DRUG","name":"Baloxavir Marboxil","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Baloxavir Marboxil","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study will evaluate the efficacy, safety, and pharmacokinetics of baloxavir marboxil in combination with a standard-of-care (SOC) neuraminidase inhibitor (NAI) (i.e., oseltamivir, zanamivir, or peramivir) compared with a matching placebo in combination with a SOC NAI in hospitalized patients with influenza.","primaryOutcome":{"measure":"Time to Clinical Improvement","timeFrame":"Up to Day 35","effectByArm":[{"arm":"Baloxavir Marboxil","deltaMin":97.5,"sd":null},{"arm":"Placebo","deltaMin":100.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.4666"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":10,"exclusionCount":14},"locations":{"siteCount":170,"countries":["United States","Argentina","Australia","Belgium","Brazil","Bulgaria","Canada","China","Czechia","Estonia","Finland","France","Germany","Hong Kong","Israel","Japan","Mexico","Netherlands","New Zealand","Peru","Romania","Serbia","Singapore","South Korea","Spain","Sweden","Turkey (TÃ¼rkiye)","Ukraine"]},"refs":{"pmids":["36171475","35085510","33248473"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":29,"n":239},"commonTop":["Constipation","Diarrhoea","Hypokalaemia","Nausea","Hepatic enzyme increased"]}}